Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net ...

Due to concerns about these chemicals’ links to cancer risks, the FDA under the Biden administration considered proposing a ban on these ingredients in certain cosmetic products such as chemical ...

Pioneering license agreement with BrainTransporter signed with BMS worth up to USD 1.35 billion plus royalties Events during the fourth quarter 2024 The Australian Medicines Agency (TGA) decided not ...

During an interview at state-run PTV-4's "Bagong Pilipinas Ngayon," FDA Director-General Samuel Zacate said that they aim to revise Department of Health Administrative Order 67 series of 1989, which ...

The pouches have been available for more than a decade as FDA reviewed company data intended to show the products can serve as an alternative to cigarettes and other traditional tobacco products.

Red Dye No. 3, or erythrosine, is a synthetic red food dye once popular in candies and cakes. The ... [+] FDA bans Red Dye No. 3 under the Delaney Clause, citing cancer risks observed in lab ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD ...

Red 3, also known as erythrosine or FD&C Red No. 3, is a red synthetic food dye used to give certain drinks, cough syrups and foods “a bright, cherry color,” according to the FDA. The agency’s report ...

MORE: RFK Jr. meets with more GOP senators amid concerns about his polio vaccine views It came five months after then-President Donald Trump proudly announced the FDA's green light of the vaccine ...

However, it had to be used in conjunction with an oral medication. The FDA has now expanded its approval to include the standalone use of the nasal spray for adults with treatment-resistant major ...

Johnson & Johnson's Spravato has been approved to treat a major depressive disorder in adults who have had an inadequate response to at least two oral antidepressants, the FDA announced Tuesday.

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the ...